August 2004
Worldwide Biotech;Aug2004, Vol. 16 Issue 8, p5
Trade Publication
Reports on the planned spin-out of the advanced anti-infectives drug portfolio of Amrad into a new corporate entity, Avexa Ltd. Amount of Amrad's shares to be given to shareholders; Statement from Amrad CEO Peter Smith on the demerger; Ongoing projects of Avexa as of August 1, 2004.


Related Articles

  • Shareholder Pressure Nixes Progen's Merger.  // Bioworld Week;3/16/2009, Vol. 17 Issue 11, p4 

    The article reports on the termination of the planned merger between biotechnological companies Progen Pharmaceutical Ltd. and Avexa Ltd. in Australia. The plan of merging was dropped as Progen stockholders have already decided to go against the merger, with about 83 percent against the deal and...

  • Buy more than the discount. Mantshantsha, Sikonathi // Finweek;9/17/2009, p39 

    The article reports on the portfolio and the development of Mvelaphanda Group Ltd. in South Africa (SA). It notes that Mvelaphanda promised to unbundle some of its assets and return value to its shareholders. The company expected to either sell or list the selected assets in a value-maximising...

  • Off the trackers. Ryan, Vincent // Telephony;06/26/2000, Vol. 238 Issue 26, p96 

    Focuses on the case of a tracking stock. Suggestions for a successful stock market; Reasons for pursuing a corporate spinoff; Status of several companies as of June 2000.

  • Expect to see spinoffs, tracking stocks in 2000. Chamberlin // San Diego Business Journal;11/29/99, Vol. 20 Issue 48, p43 

    Presents a question and answer advisory on stocks. Difference between tracking stocks and corporate spinoffs; Feasibility of giving stocks as gifts.

  • Firms Need Patience to Reap Stock Gains From Break-Ups. Sikora, Martin // Mergers & Acquisitions: The Dealermaker's Journal;Sep2002, Vol. 37 Issue 9, p22 

    Focuses on the impact of corporate spinoffs on the stocks in the U.S. Correlation between post-split stock performances and corporate spinoffs; Link between stock gains and the growth of the parent company; Recovery of the share price of the parent company.

  • Basis in spun-off subsidiary.  // Practical Accountant;Aug97, Vol. 30 Issue 8, p23 

    Reports on the rights of a parent company of an affiliated group which receives the stock of a second-tier subsidiary from a first-tier subsidiary in a spin-off transaction. Reference to the tax regulation governing this type of transaction.

  • FINANCINGS ROUNDUP.  // BioWorld Today;5/1/2009, Vol. 20 Issue 83, p4 

    This section offers news briefs related to the pharmaceutical industry. Avexa Ltd. has raised $17 million through a rights issue in which shareholders were offered one new share for every two shares held. CombiMatrix Corp. received commitments from investors to purchase $8.25 million worth of...

  • Avexa Shares Jump 45% on Apricitabine HIV Data.  // BioWorld Today;3/17/2009, Vol. 20 Issue 50, p1 

    The article reports on the increase in shares of Avexa Ltd. on positive Phase IIb data for its HIV drug apricitabine (ATC). The company reported 96-week data that showed more than 85 percent of patients continued to have HIV below detectable levels and all patients have remained on ATC...

  • Can Takeover Losses Explain Spin-Off Gains? Allen, Jeffrey W.; Lummer, Scott L.; McConnell, John J.; Reed, Debra K. // Journal of Financial & Quantitative Analysis;Dec95, Vol. 30 Issue 4, p465 

    This paper evaluates the conjecture that excess stock returns that have been documented around the announcement of corporate spin-offs represent, at least in part, the re-creation of value destroyed at the time of an earlier acquisition. We evaluate this question with a sample of spin-offs that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics